Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Molecular pathways and cellular interactions involved in HSC activation and deactivation. Activated HSCs are the main effector cells during hepatic fibrosis. In the healthy liver, they metabolize and store retinoids. Upon activation by fibrogenic stimuli, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate α-smooth muscle actin (αSMA), and produce collagen I. Various factors, including immune cell-derived fibrogenic molecules, growth factors, and lipopolysaccharide, as well as profibrotic lipid mediators such as lysophosphatidylinositol and lysophosphatidic acid, induce HSC activation in the course of chronic liver disease. TGF-β is the most HSC potent activator, which is produced by infiltrating lymphocytes and monocytes, Kupffer cells (KCs), and damaged hepatocytes. IL-17, produced by neutrophils and Th17 cells, sensitizes HSCs to TGF-β by upregulating TGF-β receptor II (TGF-βRII). In addition, platelet-derived growth factor (PDGF), which is produced by endothelial cells and macrophages, further promotes HSC activation. During fibrosis resolution, HSCs either die or revert to an inactive state by upregulating transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ), GATA-binding factor 4 (GATA4), GATA6, and transcription factor 21 (TCF21). NK and CD8+ T cells can eliminate activated HSCs by inducing apoptosis (Further abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; HH, hedgehog ligands; IHH, Indian Hedgehog; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LPS, lipopolysaccharide; miRNA, microRNA; MSR1, macrophage scavenger receptor 1; NF-κB, nuclear factor κ-light chain-enhancer of activated B cells; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; SHH, sonic hedgehog; TLR4, Toll-like receptor 4). Modified from reference [5].](https://figures.cochat.ai/paper-figures/ba56d748dfcc4395a6907c0c93306af8/liver-fibrosis-from-basic-science-towards-clinical-progress-focusing-on-the-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A pivotal element in acute and chronic liver damage is hepatic stellate cells (HSCs) activation. In response to hepatocyte injury, HSCs transition into activated myofibroblasts, overproducing extracellular matrix components and driving fibrosis (Akkız H, 2024).”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Akkız H, 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil Extracellular Traps Kill Bacteria
Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y., & Zychlinsky, A. (2004) · Science · doi:10.1126/science.1092385 · Cited by 10,268 · cited 2×
“Neutrophils are critical first responders of the innate immune system, and they can contribute to hepatic inflammation by producing proinflammatory cytokines and neutrophil extracellular traps (NETs), activating KCs, and recruiting additional types of immune cells [60–62].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 1×
“…factor, liver fibrosis reverts, going along with the decreased production of proinflammatory and profibrogenic cytokines, upregulated collagenolytic activity, the disappearance of fibrogenic cells, decreased ECM production, and, eventually, the dissolution of the fibrosis scar [1,2,4,5,13–17].”
BackgroundTGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380 · cited 3×
“Senescent HSCs are α -SMA-positive cells, but they neither proliferate nor produce collagen [2,5,10,11].”
BackgroundVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · cited 1×
“In contrast, successful antiviral treatment in patients with chronic viral hepatitis or with considerable lifestyle changes in NASH patients modulate the resolution of fibrosis [6–9].”
BackgroundInterleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372 · cited 1×
“ILCs, particularly ILC1s and ILC3s, are involved in liver fibrogenesis [82,83].”
BackgroundMolecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 10×
“…accumulation of bone marrow-derived inflammatory immune cells, secretion of proinflammatory cytokines, production of TGF-β by profibrogenic macrophages, activation of collagen type I (COLIAI)-secreting hepatic myofibroblasts, excessive production of the ECM, and the formation of a fibrous scar [4].”
BackgroundInfluentialAlcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963 · cited 1×
“In mice, the elimination of neutrophils or the deletion of neutrophil-derived soluble molecules (IL-8, IL-18, IL-17, CCL3, CCl 4 , and CCL2) attenuates the development of hepatic fibrosis [63,64].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · cited 1×
“Blocking TLR4 signaling in mice or reducing hepatic exposure to intestinal microorganisms improves liver fibrosis [81].”
BackgroundFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 10×
“The combination of low extracellular pH with an increased lactic acid level promotes myofibroblast transformation through the activation of TGF-β 1 [1,144–146].”
BackgroundInfluential
Cited by
Tauil, R. B., Golono, P. T., de Lima, E. P., Goulart, R. D. Á., Guiguer, É. L., Bechara, M. D., Nicolau, C. C. T., Yanaguizawa, J. L., Fiorini, A. M. R., Méndez‐Sánchez, N., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101354 · Cited by 85
Giangregorio, F., Mosconi, E., Debellis, M. G., Provini, S., Esposito, C., Garolfi, M., Oraka, S., KALOUDI, O., Mustafazade, G., Marín‐Baselga, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195880 · Cited by 78
“However, not all healthcare institutions have access to advanced imaging technologies like VCTE or MRE.”
BackgroundPuri, M., & Sonawane, S. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093988 · Cited by 41
“Furthermore, LSECs themselves become more susceptible to the effects of TGF-β , which contributes to their capillarization and loss of normal function [42].”
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“Conversely, hypomethylation of pro-fibrotic genes like TGF β 1 promotes sustained fibrogenic signaling, leading to continuous HSC activation and excessive ECM production [49–51].”
Metadata
- Authors
- Akkız, H., Gieseler, R. K., & Canbay, A.
- Affiliations
- Bahçeşehir University (TR)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Corresponding author
- Akkız, Hikmet
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-07-18
- Volume
- 25
- Issue
- 14
- Pages
- 7873
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11277292
- OpenAlex
- W4400775597
- Semantic Scholar
- 8810ad06f0650b984f245dec696c68e2f2723093
- Cited by
- 191
- References
- 223
- Citations by year
- 2026: 112 · 2025: 70 · 2024: 9
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cells, hepatic fibrogenesis, myofibroblast transdifferentiation, extracellular matrix deposition, hepatic stellate cell activation, HSC heterogeneity, macrophages, hepatocyte death, liver inflammation, antifibrotic therapy, cirrhosis reversal, cellular stress response, cytokines and chemokines
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Hepatic Stellate Cells, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. https://app.cochat.ai/papers/10.3390/ijms25147873
- The paper
- Akkız, H., Gieseler, R. K., & Canbay, A. (2024). Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.